Krystal Biotech (KRYS) Expected to Announce Quarterly Earnings on Monday

Key Points

• Krystal Biotech is set to release its Q2 2025 earnings data on August 4th, with analysts expecting earnings of $1.20 per share and revenue of $95.42 million.
• The company's stock price is currently around $147.61, down 1.6%, and has a market cap of $4.27 billion.
• Analysts have mixed ratings on Krystal Biotech, with an average target price of $211.33, reflecting several upgrades and downgrades from major financial institutions.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) is anticipated to announce its Q2 2025 earnings results before the market opens on Monday, August 4th. Analysts expect the company to announce earnings of $1.20 per share and revenue of $95.42 million for the quarter.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported $1.20 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.38 by ($0.18). The company had revenue of $88.18 million for the quarter, compared to analysts' expectations of $98.66 million. Krystal Biotech had a return on equity of 14.64% and a net margin of 37.17%. On average, analysts expect Krystal Biotech to post $6 EPS for the current fiscal year and $10 EPS for the next fiscal year.

Krystal Biotech Trading Up 0.7%

Shares of KRYS traded up $1.13 during mid-day trading on Thursday, reaching $154.35. 180,174 shares of the stock traded hands, compared to its average volume of 316,411. The firm has a fifty day moving average price of $139.62 and a 200 day moving average price of $155.63. The company has a market cap of $4.46 billion, a price-to-earnings ratio of 37.23 and a beta of 0.67. Krystal Biotech has a 1 year low of $122.80 and a 1 year high of $212.06.

Analyst Ratings Changes

A number of research firms recently issued reports on KRYS. HC Wainwright reissued a "buy" rating and issued a $240.00 price objective on shares of Krystal Biotech in a report on Friday, July 25th. Guggenheim dropped their price objective on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Chardan Capital reaffirmed a "buy" rating and set a $219.00 target price on shares of Krystal Biotech in a research report on Friday, July 25th. Bank of America lowered their price target on shares of Krystal Biotech from $193.00 to $192.00 and set a "buy" rating on the stock in a report on Tuesday, July 22nd. Finally, Citigroup reissued a "neutral" rating and set a $176.00 target price (up previously from $155.00) on shares of Krystal Biotech in a research note on Wednesday, July 9th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $211.33.

Insider Buying and Selling at Krystal Biotech

In related news, insider Suma Krishnan sold 13,435 shares of the stock in a transaction on Monday, July 14th. The stock was sold at an average price of $150.30, for a total value of $2,019,280.50. Following the sale, the insider owned 1,443,276 shares in the company, valued at approximately $216,924,382.80. This trade represents a 0.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In the last quarter, insiders sold 49,800 shares of company stock valued at $7,487,943. 13.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in KRYS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Krystal Biotech by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,893 shares of the company's stock worth $2,870,000 after acquiring an additional 688 shares during the period. AQR Capital Management LLC lifted its position in shares of Krystal Biotech by 29.9% in the first quarter. AQR Capital Management LLC now owns 12,131 shares of the company's stock valued at $2,187,000 after acquiring an additional 2,792 shares in the last quarter. Royal Bank of Canada raised its stake in Krystal Biotech by 145.2% during the first quarter. Royal Bank of Canada now owns 1,628 shares of the company's stock worth $294,000 after purchasing an additional 964 shares during the period. Finally, Empowered Funds LLC purchased a new stake in Krystal Biotech during the 1st quarter worth approximately $218,000. Institutional investors own 86.29% of the company's stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).